176 related articles for article (PubMed ID: 6812750)
1. Treatment of Raynaud's phenomenon with the 5-HT2-receptor antagonist ketanserin.
Stranden E; Roald OK; Krohg K
Br Med J (Clin Res Ed); 1982 Oct; 285(6348):1069-71. PubMed ID: 6812750
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Raynaud's phenomenon with ketanserin, a selective antagonist of the serotonin2 (5-HT2) receptor.
Seibold JR; Jageneau AH
Arthritis Rheum; 1984 Feb; 27(2):139-46. PubMed ID: 6365102
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Raynaud's phenomenon with ketanserin in patients with connective tissue disorders.
Roald OK; Seem E
Br Med J (Clin Res Ed); 1984 Sep; 289(6445):577-9. PubMed ID: 6432198
[TBL] [Abstract][Full Text] [Related]
4. Ketanserin (5 HT2-antagonist) in secondary Raynaud's phenomenon.
Bounameaux HM; Hellemans H; Verhaeghe R; Dequeker J
J Cardiovasc Pharmacol; 1984; 6(5):975-6. PubMed ID: 6209510
[No Abstract] [Full Text] [Related]
5. Acute effects and mechanism of action of ketanserin in patients with primary Raynaud's phenomenon.
Brouwer RM; Wenting GJ; Schalekamp MA
J Cardiovasc Pharmacol; 1990 Jun; 15(6):868-76. PubMed ID: 1694908
[TBL] [Abstract][Full Text] [Related]
6. Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial.
Lukác J; Rovenský J; Tauchmannová H; Zitnan D
Drugs Exp Clin Res; 1985; 11(9):659-63. PubMed ID: 3916837
[TBL] [Abstract][Full Text] [Related]
7. Raynaud's disease: a new therapeutic approach with a 5-HT2 receptors blocker.
Allegra C; Tonelli V; Bonifacio M; Mari A; Assogna G
Boll Chim Farm; 1985 Oct; 124(10):121S-124S. PubMed ID: 2935173
[No Abstract] [Full Text] [Related]
8. Digital blood flow and 5-hydroxytryptamine receptor blockade after ketanserin in patients with Raynaud's phenomenon.
Marasini B; Bassani C
Br J Clin Pharmacol; 1990 Dec; 30(6):847-51. PubMed ID: 2288831
[TBL] [Abstract][Full Text] [Related]
9. The use of the selective serotonin S2 receptor antagonist Ketanserin in the treatment of Raynaud's phenomenon.
Dormandy JA; Berent A; Downes SJ
Eur J Vasc Surg; 1988 Dec; 2(6):371-5. PubMed ID: 3075559
[TBL] [Abstract][Full Text] [Related]
10. Effect of chronic ketanserin treatment on serotonin-induced platelet aggregation in patients with Raynaud's phenomenon.
Marasini B; Biondi ML; Mollica R
Eur J Clin Pharmacol; 1990; 39(3):289-90. PubMed ID: 2257869
[TBL] [Abstract][Full Text] [Related]
11. Does serotonin receptor blockade have a therapeutic effect in Raynaud's phenomenon?
Brouwer RM; Wenting GJ; Visser W; Schalekamp MA
Vasa Suppl; 1987; 18():64-7. PubMed ID: 3299817
[No Abstract] [Full Text] [Related]
12. Effects of intra-arterial ketanserin in Raynaud's phenomenon assessed by 99MTc-pertechnetate scintigraphy.
Kunnen JJ; Dahler HP; Doorenspleet JG; van Oene JC
Eur J Clin Pharmacol; 1988; 34(3):267-71. PubMed ID: 2840293
[TBL] [Abstract][Full Text] [Related]
13. Effect of long-term ketanserin treatment on 5-HT levels, platelet aggregation and peripheral circulation in patients with Raynaud's phenomenon. A double-blind, placebo-controlled cross-over study.
Arneklo-Nobin B; Elmér O; Akesson A
Int Angiol; 1988; 7(1):19-25. PubMed ID: 3290356
[TBL] [Abstract][Full Text] [Related]
14. Cold hands after exposure to arsenic or vibrating tools: effects of ketanserin on finger blood pressure and skin temperature.
Lagerkvist BE; Linderholm H
Acta Pharmacol Toxicol (Copenh); 1986 May; 58(5):327-32. PubMed ID: 2943135
[TBL] [Abstract][Full Text] [Related]
15. Effects of ketanserin on peripheral blood flow, haemorheology, and platelet function in patients with Raynaud's phenomenon.
Longstaff J; Gush R; Williams EH; Jayson MI
J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S99-101. PubMed ID: 2412071
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of a selective alpha(2C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: a single-center, double-blind, placebo-controlled, randomized crossover study.
Wise RA; Wigley FM; White B; Leatherman G; Zhong J; Krasa H; Kambayashi J; Orlandi C; Czerwiec FS
Arthritis Rheum; 2004 Dec; 50(12):3994-4001. PubMed ID: 15593189
[TBL] [Abstract][Full Text] [Related]
17. Quantitative study of the effects of Ketanserin in patients with primary Raynaud's phenomenon. A randomized, double blind, placebo controlled investigation and an additional long term open trial.
van de Wal HJ; Wijn PF; van Lier HJ; Skotnicki SH
Microcirc Endothelium Lymphatics; 1985; 2(6):657-85. PubMed ID: 2942753
[TBL] [Abstract][Full Text] [Related]
18. Ketanserin and capillary flow in Raynaud's phenomenon.
Tooke JE; Williams SA; Rawlinson DW; Black C
Int J Microcirc Clin Exp; 1990 Aug; 9(3):249-55. PubMed ID: 2394546
[TBL] [Abstract][Full Text] [Related]
19. Calcitonin gene-related peptide in treatment of severe peripheral vascular insufficiency in Raynaud's phenomenon.
Bunker CB; Reavley C; O'Shaughnessy DJ; Dowd PM
Lancet; 1993 Jul; 342(8863):80-3. PubMed ID: 8100913
[TBL] [Abstract][Full Text] [Related]
20. International study of ketanserin in Raynaud's phenomenon.
Coffman JD; Clement DL; Creager MA; Dormandy JA; Janssens MM; McKendry RJ; Murray GD; Nielsen SL
Am J Med; 1989 Sep; 87(3):264-8. PubMed ID: 2672807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
